Möchten Sie immer auf dem neuesten Stand bleiben?

Oslo (Norway), 7 September 2023 – PCI Biotech (OSE: PCIB), a biopharmaceutical company, today announces that the European Patent Office (EPO) has informed PCI Biotech that they intend to grant a new...

Oslo, 4 September 2023 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees.         In accordance with the authorisation granted by the...

Oslo, Norway, 1 September 2023 – PCI Biotech Holding ASA (OSE: PCIB) Reference is made to the resolution made by the Annual General Meeting 25 May 2023, in respect of a write-down of share capital by...

Oslo (Norway), 31 August 2023 – PCI Biotech (OSE: PCIB), today announces its interim first half 2023 results. Please find enclosed the report and presentation.Highlights review fimaNAc –...

Oslo, Norway, 25 August 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2023 interim report on Thursday 31 August 2023, 08:30am – 09:30am CEST (local...

Oslo, 25 May 2023. The Annual General Meeting in PCI Biotech Holding ASA took place today, 25 May 2023. All the matters on the agenda were approved and the minutes of the Annual General Meeting are...

Oslo, 24 May 2023. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall...

Oslo (Norway), 12 May 2023 – PCI Biotech (OSE: PCIB), today announces its interim Q1 2023 results. Please find enclosed the report and presentation. Highlights reviewfimaNAc – bioprocessingThe...

Oslo, Norway, 9 May 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's Q1 2023 interim report on Friday 12 May 2023, 08:30am – 09:30am CEST (local time). The...

Oslo, Norway 4 May 2023 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 25 May 2023 at 10:00am (CEST). The...